Close Menu

Cepheid

ISS astronauts will soon begin testing the Oxford Nanopore MinIon and two PCR platforms while researchers on Earth continue to evaluate microarrays for use in space.

The firm postponed the launch to enhance Omni's capabilities, in the meantime focusing on opportunities in near-patient testing for its GeneXpert system.

Total revenues were $144.8 million, a 13 percent increase on a constant currency basis, and beating the average analysts' estimate of $140.2 million.

Evidence is mounting supporting the use of self-collected specimens for HPV and other infectious disease testing in both the developing and developed world.

The partnership is the second this year aimed at widening distribution of the GeneXpert to moderately complex labs in the US. 

The upgraded test includes new gene targets for methicillin resistance, and provides room-temperature storage and validation on multiple swab types.

The test is the 20th US-IVD molecular diagnostic on the GeneXpert menu — Cepheid also recently announced that it has now placed its 10,000 systems globally.

The firm attributed the growth to record reagent revenues and GeneXpert system placements. 

Executives from several life science research tool and diagnostic firms provided conference attendees with updates on their businesses.

Cepheid will create Xpert cartridge tests to detect S. aureus and P. aeuginosa, to be used in clinical trials for biologics intended to prevent pneumonia.

Pages

Mainichi reports that 43 percent of Japanese individuals said they did not want to eat agricultural products that had been modified using gene-editing tools.

Two US Department of Agriculture research departments are moving to the Kansas City area, according to the Washington Post.

Slate's Jane Hu compares some at-home genetic tests to astrology.

In PLOS this week: analysis of polygenic risk scores for skin cancer, chronic pain GWAS, and more.